Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this research is to see to what extent electrical stimulation applied to the scalp (transcranial direct current stimulation or tDCS) can reduce the number and intensity of epileptic seizures.
tDCS for treatment of epilepsy has been studied previously with results suggesting that it can lead to a notable seizure reduction for a limited time period after the cessation of stimulation, e.g., about one month. Here, we assess further aspects of tDCS treatment protocols, including the feasibility and safety of at-home use.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| tDCS Treatment A (Low Amplitude) | Experimental | Subjects with focal epilepsy that is not well-controlled on anti-seizure medications will receive 2 different treatments periods, each lasting 2 months, of transcranial direct current stimulation (tDCS). The initial treatment stimulation will be completed during the first 2-months. |
|
| tDCS Treatment B (High Amplitude) | Experimental | Subjects with focal epilepsy that is not well-controlled on anti-seizure medications will receive 2 different treatments periods, each lasting 2 months, of transcranial direct current stimulation (tDCS). The last treatment stimulation will be completed during the following 2-months. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ActivaDose II 0.1 mA transcranial direct current stimulation (tDCS) | Device | Stimulation setting 0.1 mA daily for a 2-month period. Each daily treatment will last for approximately 30 minutes. |
| Measure | Description | Time Frame |
|---|---|---|
| Seizure Count | Number of seizures experienced by subjects as determined by self-reported seizure diary | 2 months |
| Measure | Description | Time Frame |
|---|---|---|
| EEG interictal discharge frequency | Number of interictal epileptiform discharges observed on electroencephalogram (EEG) | 2 months |
Not provided
Inclusion Criteria
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Precylla Ruiz | Contact | 507-538-6606 | ruiz.precylla@mayo.edu | |
| Izzie Meunier | Contact | 507-538-6337 | meunier.isabelle@mayo.edu |
| Name | Affiliation | Role |
|---|---|---|
| Brian Lundstrom, MD, PhD | Mayo Clinic | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mayo Clinic Minnesota | Recruiting | Rochester | Minnesota | 55905 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ActivaDose II 2.0 mA transcranial direct current stimulation (tDCS) | Device | Stimulation setting 2.0 mA daily for a 2-month period. A Each daily treatment will last for approximately 30 minutes. |
|
| ID | Term |
|---|---|
| D004828 | Epilepsies, Partial |
| ID | Term |
|---|---|
| D004827 | Epilepsy |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided